U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
47.65+0.15 (+0.32%)
At close: 4:00PM EDT

47.65 0.00 (0.00%)
After hours: 4:27PM EDT

People also watch
IMGNBMRNINCYALNYCLDX
  • F
    Finkelstein
    Finkelstein

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • T
    Trent
    Trent
    52 week low on recent submission to the FDA with expedited decision ? Strange.
  • M
    Maurizio
    Maurizio
    Have we finally bottomed???!!!
  • G
    GreatDayStockGuruInCA
    GreatDayStockGuruInCA
    Eyeing SGEN here near 52 week LOW! Also like ACRX, with an Oct 12th FDA APPROVAL date for Dsuvia, with peak U.S. sales estimated at over $1 billion dollars...
  • A
    Anonymous
    Anonymous
    Over 200k shares awarded to executive staff at this point in time (vesting over 4 years) would seem to be bullish timing.
    Paladin
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    Looks like Bakers may be buying. Just a hunch. We will see soon. Someone is jumping in though.
  • N
    Natalie
    Natalie
    Do you think this thing is done selling? Showing us a buy signal now on SGEN? awesom_sto-cks recently alerted this company i think. google them.
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    Bakers silent since November. Hope they don't add to position. Thinking there setting up for sale or they would be pouncing at a mid 40 price. Especially since they pounced at mid 50's in November. 46 Friday and then mid 90's takeout over one of these weekends. Cmon Felix. Let the baby rip!
  • D
    Diane
    Diane
    Any stock that tanks 30 bucks is due for a rebound. BUY NOW.
  • f
    flickr
    flickr

    Don't forget this could be SGEN at ASH.

    Roche Holding AG RHHBY -0.08% shares jumped 6.5% on a single day in early March when the drugmaker said its new breast-cancer treatment, Perjeta, helped prolong average patient survival in a clinical study.

    But the stock gave up nearly all those gains three months later, when the Swiss company disclosed full details of the trial at a medical conference. The study, dubbed Aphinity, showed what some doctors said was only a marginal benefit for Perjeta, and investors, initially hopeful of a big sales boost for the drug, lowered their expectations.

    https://www.wsj.com/articles/some-investors-feel-burned-by-drugmakers-clinical-trial-reports-1502712000?tesla=y&mod=e2tw

    Some Investors Feel Burned by Drugmakers’ Clinical-Trial Reports
    Roche angered some U.S. shareholders when a medical presentation about a clinical-trial involving the cancer drug Perjeta didn’t bear out the drugmaker’s earlier upbeat disclosures.
    www.wsj.com
  • c
    chrag
    chrag
    10 dollar is where this belongs
    Look what Baker Brothers did to Immunogen ( IMGN)...pumped it to 17 with half-a#$ phase 2 data on mirvetuximab and is now a 6 dollar stock.
  • D
    Diane
    Diane
    AQXP-Told ya. Baker's controlling both SGEN and AQXP.
  • r
    ron
    ron
    Bakers selling any of this crud?
  • B
    BillB
    BillB
    Any thoughts out there on the purchase of the Bothall manufacturing facility? Will this allow for faster rollout of any new drugs? Will there be any opportunities to use these facilities to capture additional revenue by producing other companies medicines? Thanks in advance to any knowledgeable posters. These boards used to provide so much good info--since Yahoo revised them, not much of value hits. I did like your previous post Anonymous--it was very thoughtful and well supported factually. Thank you!!
  • f
    flickr
    flickr
    Sold it all today. It's a shame but 50.00 was my trigger. Technical support levels now are around 45 and if that doesn't hold you are looking at 35.00. My biggest fear is ASH. The press release on Echelon 1 mentions the 82 % PFS but states nothing about pulmonary tox. Pulmonary tox is associated with Adcetris (black box warning, and the argument for E1 financial success is that removing Bleomycin would get rid of it in 11 % of patients. However, it's unknown if AVD Adcetris combo decreases p. tox. if not uh hoh.
  • m
    michael
    michael
    When it is all said and done, blowing the gift that was the IMMU deal will loom large in the future of SGEN. IMMU 132 is potentially the multibillion dollar therapy that you all have been praying for. And it was right there...
  • .
    .
    .
    Is this turd rocket seriously down to $49.22? Remember the good old days when it was $68? Will this POS ever stop bleeding?
  • r
    redhot47fla
    redhot47fla
    From our misery-loves-company file comes this observation from someone on Twitter: "Bakers position only down $1.2 billion since hitting 52 week highs."
  • r
    ron
    ron
    Hope to see a pop, so I can a chunk. This a roller coaster without thrills.